Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Fragment synthesis of cyclic peptides
US2020361944A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020361944-A1 |
| Application number | US-202016985096-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 4, 2020 |
| Priority date | Nov 11, 2015 |
| Publication date | Nov 19, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is described herein use of a compound of formula (I) below to make cyclic peptides.
First claim
Opening claim text (preview).
1 . A compound of formula (IIb): wherein —(C═O)-L-Z has a formula selected from: 2 . The compound of claim 1 , wherein —(C═O)-L-Z is: 3 . The compound of claim 2 selected from the group consisting of 4 . The compound of claim 1 , wherein —(C═O)-L-Z is: 5 . The compound of claim 4 , wherein the compound is: 6 . The compound of claim 1 , wherein —(C═O)-L-Z is: 7 . The compound of claim 6 , wherein the compound is: 8 . The compound of claim 1 , wherein —(C═O)-L-Z is: 9 . The compound of claim 8 , wherein the compound is: 10 . The compound of claim 1 , wherein —(C═O)-L-Z is: 11 . The compound of claim 10 , wherein the compound is: 12 . A compound selected from the group consisting of:
Assignees
Inventors
Classifications
Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020361944A1 cover?
- There is described herein use of a compound of formula (I) below to make cyclic peptides.
- Who is the assignee on this patent?
- Encycle Therapeutics Inc, Univ Montreal
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).